Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Yumanity Therapeutics Inc (YMTX)

Yumanity Therapeutics Inc (YMTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,021
  • Shares Outstanding, K 10,856
  • Annual Sales, $ 8,040 K
  • Annual Income, $ -39,500 K
  • 60-Month Beta 0.31
  • Price/Sales 2.25
  • Price/Cash Flow N/A
  • Price/Book 2.25
Trade YMTX with:

Options Overview Details

View History
  • Implied Volatility 305.91% ( -7.16%)
  • Historical Volatility 39.40%
  • IV Percentile 81%
  • IV Rank 32.86%
  • IV High 834.11% on 05/31/22
  • IV Low 47.35% on 01/10/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 2,064
  • Open Int (30-Day) 1,954

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.16
  • Number of Estimates 1
  • High Estimate -1.16
  • Low Estimate -1.16
  • Prior Year -0.97
  • Growth Rate Est. (year over year) -19.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4900 +11.41%
on 08/01/22
1.7900 -7.26%
on 07/19/22
-0.0200 (-1.19%)
since 07/18/22
3-Month
1.0200 +62.75%
on 05/25/22
2.1900 -24.20%
on 06/06/22
+0.5500 (+49.55%)
since 05/18/22
52-Week
0.9500 +74.74%
on 03/14/22
13.9000 -88.06%
on 09/16/21
-7.2600 (-81.39%)
since 08/18/21

Most Recent Stories

More News
Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical...

YMTX : 1.6600 (-0.60%)
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates TPTX, DRE, CVET, YMTX

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TPTX : 76.01 (+0.69%)
DRE : 64.61 (-0.42%)
CVET : 20.83 (+0.05%)
YMTX : 1.6600 (-0.60%)
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) (the “Company”)...

YMTX : 1.6600 (-0.60%)
YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Yumanity Therapeutics, Inc. - YMTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) (the “Company”)...

YMTX : 1.6600 (-0.60%)
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product...

YMTX : 1.6600 (-0.60%)
Yumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue Estimates

Yumanity (YMTX) delivered earnings and revenue surprises of -21.57% and 31.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

YMTX : 1.6600 (-0.60%)
SLHG : 0.6201 (-0.26%)
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and...

YMTX : 1.6600 (-0.60%)
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

RVNC : 22.23 (+2.54%)
YMTX : 1.6600 (-0.60%)
Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EIGR : 9.30 (-1.17%)
YMTX : 1.6600 (-0.60%)
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments

BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and...

YMTX : 1.6600 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. The company's product candidate includes YTX-7739.Yumanity Therapeutics Inc., formerly known as Proteostasis Therapeutics Inc., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 1.7433
2nd Resistance Point 1.7267
1st Resistance Point 1.6933
Last Price 1.6600
1st Support Level 1.6433
2nd Support Level 1.6267
3rd Support Level 1.5933

See More

52-Week High 13.9000
Fibonacci 61.8% 8.9531
Fibonacci 50% 7.4250
Fibonacci 38.2% 5.8969
Last Price 1.6600
52-Week Low 0.9500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar